Article
Medicine, General & Internal
Katarina Glise Sandblad, Sam Schulman, Annika Rosengren, Jan Sorbo, Jacob Philipson, Per-Olof Hansson
Summary: Apixaban has a lower bleeding risk than warfarin or rivaroxaban during initial treatment, and comparable risk with rivaroxaban during extended treatment.
JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Public, Environmental & Occupational Health
Efe Eworuke, Laura Hou, Rongmei Zhang, Hui-Lee Wong, Peter Waldron, Abby Anderson, Audrey Gassman, David Moeny, Ting-Ying Huang
Summary: This study found an increased risk of severe abnormal uterine bleeding with the use of rivaroxaban compared to other direct oral anticoagulants or warfarin. The risk of severe abnormal uterine bleeding with rivaroxaban was present among women without underlying gynecological conditions. Women on anticoagulant therapy should be aware of this risk.
Article
Hematology
Laurent Bertoletti, Gaelle Gusto, Artak Khachatryan, Nadia Quignot, Jose Chaves, Audrey Moniot, Ruth Mokgokong
Summary: DOACs have been found to be noninferior and safer than conventional therapy for treating VTE in clinical trials. This observational study compares the effectiveness and safety of DOACs and conventional therapy in a real-world setting, and finds that DOACs are associated with superior safety and effectiveness.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Hematology
C. M. M. de Jong, M. Blondon, C. Ay, A. Buchmuller, J. Beyer-Westendorf, J. Biechele, L. Bertoletti, G. Colombo, M. P. Donadini, S. V. Hendriks, L. Jara-Palomares, S. Nopp, P. Ruiz-Artacho, P. Stephan, C. Tromeur, T. Vanassche, P. E. Westerweel, F. A. Klok
Summary: Preliminary data and clinical experience suggest an increased risk of abnormal uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but there is a lack of solid data. In a study involving 98 women diagnosed with acute venous thromboembolism (VTE), 2 out of 3 women experienced AUB during anticoagulation treatment, with a significant negative impact on their quality of life (QoL).
Article
Medicine, General & Internal
Paolo Santini, Carolina Mosoni, Alessandro D'Errico, Enrica Porceddu, Andrea Lupascu, Emanuele Valeriani, Paolo Tondi, Roberto Pola, Angelo Porfidia
Summary: This study evaluated the effectiveness and safety of low-dose rivaroxaban for the prevention of recurrent venous thromboembolism (VTE) in cancer patients. The results showed that low-dose rivaroxaban was potentially effective and safe in this patient population.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Hematology
Judith Catella, Laurent Bertoletti, Fares Moustafa, Jose Antonio Nieto, Reina Valle, Jose Maria Pedrajas, Aurora Villalobos, Isabelle Quere, Gabrielle Sarlon-Bartoli, Manuel Monreal
Summary: In this study, we assessed the clinical characteristics of patients developing major gastrointestinal bleeding during anticoagulation therapy and developed a predictive score to identify patients at increased risk. The score showed potential in identifying high-risk patients, but further validation is needed.
THROMBOSIS RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Ida Ehlers Albertsen, Martin Jensen, Khaled Abdelgawwad, Mette Sogaard, Torben Bjerregaard Larsen, Peter Bronnum Nielsen
Summary: The study found that less than 3% of VTE patients received extended treatment after initial standard treatment, and after adjustments, it was found that patients with incident pulmonary embolism and trauma/fracture were more likely to receive extended doses, while patients with unprovoked VTE were less likely to receive extended doses.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2021)
Article
Medicine, General & Internal
Mei-Chuan Lee, Chia-Te Liao, I-Jung Feng, Tsung Yu, Wei-Ting Chang, Mei-Fen Shih, Hui-Chen Su, Han Siong Toh
Summary: This study compared the risks of recurrent VTE, bleeding, and mortality between Taiwanese VTE patients receiving rivaroxaban and those receiving heparin or LMWH followed by warfarin. The results showed that rivaroxaban did not lower the risks of recurrent VTE and mortality, and did not significantly increase the risk of major bleeding.
Article
Cardiac & Cardiovascular Systems
Maria A. de Winter, Harry R. Buller, Marc Carrier, Alexander T. Cohen, John-Bjarne Hansen, Karin A. H. Kaasjager, Ajay K. Kakkar, Saskia Middeldorp, Gary E. Raskob, Henrik T. Sorensen, Frank L. J. Visseren, Philip S. Wells, Jannick A. N. Dorresteijn, Mathilde Nijkeuter, VTE PREDICT study Grp
Summary: This study aimed to develop and validate models for predicting 5-year risks of recurrence and bleeding in VTE patients without cancer. The models were derived from patient data and validated externally, showing good agreement between predicted and observed risks for up to 5 years.
EUROPEAN HEART JOURNAL
(2023)
Article
Hematology
Ingrid M. Bistervels, Roisin Bavalia, Martin Gebel, Anthonie W. A. Lensing, Saskia Middeldorp, Martin H. Prins, Michiel Coppens
Summary: Polypharmacy, including use of CYP3A4 and P-gp inhibitors, is common in venous thromboembolism (VTE) patients and is associated with increased bleeding. However, fixed-dose rivaroxaban is not associated with increased bleeding risk compared to enoxaparin/VKA in patients receiving polypharmacy and CYP3A4 and/or P-gp inhibitors. The increased bleeding risks observed with polypharmacy and use of CYP3A4 and/or P-gp inhibitors are likely explained by comorbidities and frailty, rather than pharmacokinetic interactions.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Cardiac & Cardiovascular Systems
Valerie M. Vaughn, David Ratz, Elizabeth S. McLaughlin, Jennifer K. Horowitz, Scott A. Flanders, Elizabeth A. Middleton, Paul J. Grant, Scott Kaatz, Geoffrey D. Barnes
Summary: A study showed that extending the use of prophylactic rivaroxaban during hospitalization of COVID-19 patients to 35 days can improve post-hospital outcomes. However, only about one in four patients actually qualify for this standard, with a very small portion of them receiving a new prescription for anticoagulants upon discharge.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Olivia S. Costa, Jan Beyer-Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J. Bunz, Craig Coleman
Summary: The prescription of rivaroxaban in obese VTE patients was associated with a significantly reduced risk of recurrent VTE compared to warfarin, without affecting major bleeding. These findings remained consistent across different BMI categories.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Review
Medicine, Research & Experimental
Stefano Ballestri, Elisa Romagnoli, Dimitriy Arioli, Valeria Coluccio, Alessandra Marrazzo, Afroditi Athanasiou, Maria Di Girolamo, Cinzia Cappi, Marco Marietta, Mariano Capitelli
Summary: This article systematically evaluates the risk of bleeding complications of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) in patients with atrial fibrillation and venous thromboembolism. It also discusses the management of bleeding complications and the possibility of resuming anticoagulation for special patient populations. Recommendations for choosing the optimal DOAC to minimize adverse events according to individual patient characteristics and bleeding risk are provided.
ADVANCES IN THERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Gary E. Raskob, Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, Elliot S. Barnathan
Summary: The study found that using rivaroxaban 10 mg once daily for thromboprophylaxis can effectively reduce the incidence of major thromboembolic events, with a favorable trade-off to fatal or critical site bleeding.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Hematology
Scott D. Berkowitz, Rupert M. Bauersachs, Michael Szarek, Mark R. Nehler, E. Sebastian Debus, Manesh R. Patel, Sonia S. Anand, Warren H. Capell, Connie N. Hess, Judy Hsia, Nicholas J. Leeper, David Brasil, Lajos Matyas, Rafael Diaz, Marianne Brodmann, Eva Muehlhofer, Lloyd P. Haskell, Marc P. Bonaca
Summary: Assessing total arterial and venous thrombotic events, not just first events, provides more complete information about disease burden and treatment impact. Adding low-dose anticoagulation to low-dose antiplatelet therapy can reduce the occurrence of arterial and venous thrombotic events.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Cardiac & Cardiovascular Systems
Pieter Martens, Chantal Mathieu, Thomas Vanassche
Summary: The presence of type 2 diabetes puts patients at a higher risk for cardiovascular disease, heart failure, and chronic kidney disease. Glucose control alone is not enough to prevent these complications, but new drugs like SGLT2-I and GLP-1RA show promise in reducing these risks. However, the uptake of these drugs in clinical practice, especially GLP-1RA, is low.
Article
Hematology
Alexander G. G. Turpie, Alfredo E. Farjat, Sylvia Haas, Walter Ageno, Jeffrey Weitz, Samuel Z. Goldhaber, Shinya Goto, Pantep Angchaisuksiri, Gloria Kayani, Renato D. Lopes, Chern-En Chiang, Harry Gibbs, Eric Tse, Peter Verhamme, Hugo ten Cate, Juan Muntaner, Sebastian Schellong, Henri Bounameaux, Paolo Prandoni, Uma Maheshwari, Ajay K. Kakkar
Summary: GARFIELD-VTE is an observational study that aims to collect clinical data of patients with deep vein thrombosis and pulmonary embolism worldwide. The study found that the highest accumulation of events occurred within the first 12 months after diagnosis, which may help identify treatment gaps and improve patient outcomes.
THROMBOSIS RESEARCH
(2023)
Article
Critical Care Medicine
Lore Vanderbeke, Cato Jacobs, Simon Feys, Agustin Resendiz-Sharpe, Yves Debaveye, Greet Hermans, Stephanie Humblet-Baron, Katrien Lagrou, Philippe Meersseman, Marijke Peetermans, Laura Seldeslachts, Arno Vanstapel, Greetje Vande Velde, Eric Van Wijngaerden, Alexander Wilmer, Erik Verbeken, Gert De Hertogh, Joost Wauters
Summary: This study investigated the invasive nature of pulmonary aspergillosis in histology specimens of influenza and COVID-19 ICU fatalities. It found that both influenza and COVID-19 patients can develop invasive pulmonary aspergillosis with similar histological patterns.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Lorenz Van der Linden, Thomas Vanassche, Eric Van Cutsem, Lucas Van Aelst, Peter Verhamme
Summary: Drug-drug interactions (DDIs) between direct oral anticoagulants (DOACs) and cancer therapies pose a risk in the management of cancer-associated thrombosis. This review provides practical guidance and a framework for clinicians to understand and navigate the potential pharmacokinetic interactions between DOACs and cancer therapies.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Dongmei Wei, Vannina Gonzalez-Marrachelli, Jesus D. Melgarejo, Chia-Te Liao, Angie Hu, Stefan Janssens, Peter Verhamme, Lucas Van Aelst, Thomas Vanassche, Josep Redon, Maria Tellez-Plaza, Juan C. Martin-Escudero, Daniel Monleon, Zhen-Yu Zhang
Summary: A new definition of metabolically healthy obesity (MHO) has been proposed to stratify the mortality risk of obesity. This study aimed to evaluate the association between MHO and cardiovascular events and assess its metabolomic pattern.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Jr Tuman J. Milling, Saskia Middeldorp, Lizhen Xu, Bruce Koch, Andrew Demchuk, John W. Eikelboom, Peter Verhamme, Alexander T. Cohen, Jan Beyer-Westendorf, C. Michael Gibson, Jose Lopez-Sendon, Mark Crowther, Ashkan Shoamanesh, Michiel Coppens, Jeannot Schmidt, Pierre Albaladejo, Stuart J. Connolly
Summary: This study evaluated the safety and efficacy of andexanet alfa in patients with major bleeding caused by factor Xa inhibitors. The results showed that the drug reduced anti-FXa activity and achieved good or excellent hemostatic efficacy in 80% of the patients.
Article
Cardiac & Cardiovascular Systems
Dongmei Wei, Jesus D. Melgarejo, Lucas Van Aelst, Thomas Vanassche, Peter Verhamme, Stefan Janssens, Karlheinz Peter, Zhen-Yu Zhang
Summary: A urinary proteomic classifier related to collagen metabolism, lipids, and inflammation was developed and validated for the prediction of coronary artery disease (CAD). This novel classifier improves the risk reclassification on top of the clinical risk score, offering an alternative approach to personalized prevention.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Immunology
Simon Feys, Katrien Lagrou, Hanne Moon Lauwers, Koen Haenen, Cato Jacobs, Marius Brusselmans, Yves Debaveye, Greet Hermans, Martin Hoenigl, Johan Maertens, Philippe Meersseman, Marijke Peetermans, Isabel Spriet, Christophe Vandenbriele, Lore Vanderbeke, Robin Vos, Eric Van Wijngaerden, Alexander Wilmer, Joost Wauters
Summary: COVID-19-associated pulmonary aspergillosis (CAPA) occurs frequently in critically ill patients with COVID-19, especially in severely immunocompromised patients. The incidence of CAPA increases significantly during the vaccination era and is associated with higher mortality rates.
CLINICAL INFECTIOUS DISEASES
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Marc Carrier, Peter Verhamme
EUROPEAN HEART JOURNAL
(2023)
Article
Biology
Caroline P. Martens, Marijke Peetermans, Thomas Vanassche, Peter Verhamme, Marc Jacquemin, Kimberly Martinod
Summary: Staphylococcus aureus infection is associated with increased levels of neutrophil extracellular traps (NETs) and von Willebrand factor (VWF), and with reduced activity of ADAMTS13. Peptidylarginine deiminase 4 (PAD4) contributes to NET formation and inactivates ADAMTS13 in vitro. The levels of PADs correlate with ADAMTS13 activity, with neutrophils as the likely source of PAD activity in S. aureus infection. NETs are positively correlated with PADs and negatively correlated with ADAMTS13 activity.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
(2023)
Review
Medicine, General & Internal
Thomas Vanassche, Matthias M. Engelen, Christelle Orlando, Kristel Vandenbosch, Alain Gadisseur, Cedric Hermans, Kristin Jochmans, Jean-Marc Minon, Serge Motte, Harlinde Peperstraete, Pierre Peters, Muriel Sprynger, Patrizio Lancellotti, Isabelle Dehaene, Patrick Emonts, Christophe Vandenbriele, Peter Verhamme, Cecile Oury
Summary: COVID-19 is associated with an increased risk for thrombotic complications. The trials investigating the optimal thromboprophylactic dose produce conflicting evidence due to challenging circumstances, divergent endpoints, and different analytical approaches. Nevertheless, clinicians should provide thromboprophylaxis in hospitalized COVID-19 patients, while assessing bleeding and thrombotic risk frequently. The updated guidance document by the COVID-19 Thromboprophylaxis Working Group of the BSTH aims to critically summarize available evidence and guide clinicians in providing the best possible thromboprophylaxis.
ACTA CLINICA BELGICA
(2023)
Article
Hematology
Christine Van Laer, Marc Jacquemin, Sarissa Baert, Veerle Labarque, Chantal Thys, Thomas Vanassche, Chris Van Geet, Peter Verhamme, Karen Willekens, Anniek Corveleyn, Kathelijne Peerlinck, Kathleen Freson
Summary: This study focuses on the implementation of genetic testing for inherited bleeding, thrombotic, and platelet disorders in Belgian clinical practice. The results highlight the challenges in interpreting genetic results and suggest the need for continuous optimization of diagnostic outcomes. Variants were reclassified and submitted to the ISTH's GoldVariants database.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Meeting Abstract
Peripheral Vascular Disease
Ryan Trouve, Dongmei Wei, Thomas Vanassche, Lucas Van Aelst, Peter Verhamme, Stafen Janssens, Zhen-Yu Zhang
JOURNAL OF HYPERTENSION
(2023)
Meeting Abstract
Peripheral Vascular Disease
Dongmei Wei, Jesus D. Melgare, Lucas van Aelst, Thomas Vanassche, Peter Verhamme, Stefan Janssens, Karlheinz Peter, Zhen-Yu Zhang
JOURNAL OF HYPERTENSION
(2023)
Meeting Abstract
Peripheral Vascular Disease
Yuling Yu, Paula Moliterno, Dewei An, Anke Raaijmakers, Dries Martens, Katarzyna Stolarz-Skrzypek, Valerie Tikhonoff, Sofia Malyutina, Edoardo Casiglia, Babangida Chori, Jan Filipovsky, Marek Rajzer, Karel Allegaert, Kalina Kawecka-Jaszcz, Peter Verhamme, Tim Nawrot, Jan Staessen, Jose Boggia
JOURNAL OF HYPERTENSION
(2023)
Article
Hematology
E. O. Artemenko, S. I. Obydennyi, K. S. Troyanova, G. A. Novichkova, D. Y. Nechipurenko, M. A. Panteleev
Summary: In this study, we investigated the adhesive properties of circulating plasma-derived and platelet-derived microvesicles (MVs) and their potential role in thrombus growth. The results showed that both types of MVs weakly bound fibrinogen but did not stably adhere to immobilized fibrinogen. Moreover, the presence of these MVs did not significantly affect thrombus formation. Therefore, MVs present in the plasma of healthy individuals are unlikely to directly contribute to thrombus formation under arterial flow conditions.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J. Favaloro
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marium Malik, Maha Al-Ghafry, Abraham Haimed, Julia Su, Maribel Lema, Linda Shore-Lessersson, Suchitra S. Acharya
Summary: This study analyzed and evaluated leukemia-associated coagulopathy in newly diagnosed pediatric leukemia patients using CCTs and ROTEM. The results showed that fibrinogen and platelets played a significant role in causing coagulopathies in this population. This suggests the utility of using CCTs and ROTEM in the pediatric population to evaluate hemostatic function and guide blood product replacement.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Mohammad M. Elahi, Alexandra N. Witt, Edward L. G. Pryzdial, Paul B. McBeth
Summary: Thrombotic disease may be underdiagnosed in microgravity conditions, and the underlying factors are still poorly understood. A case of internal jugular vein thrombosis was recently diagnosed in a low-risk female astronaut, and six out of ten additional crew members showed risk factors for jugular venous flow. Observations in space and studies on Earth suggest that microgravity affects blood flow, coagulation, and vascular function.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Stian Ingemann-Molden, Christina Krogner Caspersen, Nanna Rolving, Anette Arbjerg Hojen, Frederikus A. Klok, Erik L. Grove, Barbara Cristina Brocki, Jane Andreasen
Summary: This study found that no single PROM covered all aspects considered important by PE patients. PROMs recommended in the ICHOM core set covered most aspects, but worrisome thoughts, hypervigilance around symptoms, and uncertainty of illness were not covered.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Haomin Yan, Tsutomu Sasaki, Yasufumi Gon, Kumiko Nishiyama, Hideaki Kanki, Hideki Mochizuki
Summary: The incidence of cancer-associated stroke has increased with the prolonged survival times of cancer patients. In this study, the researchers focused on the driver gene KRAS and found that KRAS mutations exacerbated neurological deficits after stroke and promoted tumor growth. They also identified the upregulation of pro-inflammatory responses and the promotion of STAT3 phosphorylation in mice with KRAS mutations. Additionally, the researchers found that colorectal cancer patients with stroke onset within 3 months after cancer diagnosis had a worse prognosis.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Tomoki Togashi, Satomi Nagaya, Makiko Meguro-Horike, Haruto Matsumoto, Yuta Imai, Koichi Yamaguchi, Yoshinari Fujii, Haruka Moriya, Yuika Kikuchi, Ibuki Yasuda, Shin-ichi Horike, Eriko Morishita
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marta Najarro, Winnifer Briceno, Carmen Rodriguez, Alfonso Muriel, Sara Gonzalez, Ana Castillo, Ignacio Jara, Parth Rali, Catalin Toma, Behnood Bikdeli, David Jimenez
Summary: The CPES score is a useful tool in identifying the risk of hemodynamic deterioration in normotensive patients with acute PE, with acceptable C-statistic, excellent specificity, and low positive predictive value.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Lei Liu, Huifang Xu, Jian Wang, Haiyan Wang, Saisai Ren, Qian Huang, Mingyan Zhang, Hui Zhou, Chunyan Yang, Lu Jia, Yu Huang, Hao Zhang, Yanling Tao, Ying Li, Yanan Min
Summary: This study investigated the gut microbiota metabolites and cytokines, chemokines, and growth factors in patients with ITP and found their association with treatment responsiveness. The findings suggest that imbalanced secretion of cyto(chemo)kins/growth factors and inadequate levels of TMAO are characteristic of patients with ITP.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Roxanne Mcknight, Mohammad Salameh, Lee Ann Jones, Greta Anton, Lindsay Carter
Summary: This study evaluated the safety of fixed-dose heparin titration boluses in underweight patients with VTE. The results showed that although underweight patients required more frequent holding of heparin, there was no significant increase in bleeding risk.
THROMBOSIS RESEARCH
(2024)